Skandinaviska Enskilda Banken Ab (Publ) Krystal Biotech, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 89,047 shares of KRYS stock, worth $16.4 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
89,047
Previous 126,082
29.37%
Holding current value
$16.4 Million
Previous $22.9 Million
39.16%
% of portfolio
0.06%
Previous 0.11%
Shares
14 transactions
Others Institutions Holding KRYS
# of Institutions
300Shares Held
24.3MCall Options Held
388KPut Options Held
233K-
Black Rock Inc. New York, NY3.95MShares$725 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$529 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$483 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$235 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA879KShares$162 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.72B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...